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SUMMARY
Cost‐effectiveness analyses (CEA) conducted alongside randomised trials pro-
vide key evidence for informing healthcare decision making, but missing data
pose substantive challenges. Recently, there have been a number of develop-
ments in methods and guidelines addressing missing data in trials. However,
it is unclear whether these developments have permeated CEA practice. This
paper critically reviews the extent of and methods used to address missing data
in recently published trial‐based CEA.
Issues of the Health Technology Assessment journal from 2013 to 2015 were
searched. Fifty‐two eligible studies were identified. Missing data were very com-
mon; the median proportion of trial participants with complete cost‐effective-
ness data was 63% (interquartile range: 47%–81%). The most common
approach for the primary analysis was to restrict analysis to those with com-
plete data (43%), followed by multiple imputation (30%). Half of the studies con-
ducted some sort of sensitivity analyses, but only 2 (4%) considered possible
departures from the missing‐at‐random assumption.
Further improvements are needed to address missing data in cost‐effectiveness
analyses conducted alongside randomised trials. These should focus on limiting
the extent of missing data, choosing an appropriate method for the primary
analysis that is valid under contextually plausible assumptions, and conducting
sensitivity analyses to departures from the missing‐at‐random assumption.
KEYWORDS
cost‐effectiveness analysis, missing data, multiple imputation, randomised controlled trials, sensitivity
analysis
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1 | INTRODUCTION
Cost‐effectiveness analyses (CEA) conducted alongside randomised controlled trials are an important source of information
for health commissioners and decisionmakers. However, clinical trials rarely succeed in collecting all the intended informa-
tion (Bell, Fiero, Horton, & Hsu, 2014), and inappropriate handling of the resulting missing data can lead to misleading
inferences (Little et al., 2012). This issue is particularly pronounced in CEA because these usually rely on collecting rich,
longitudinal information from participants, such as their use of healthcare services (e.g., Client Service Receipt Inventory;
Beecham & Knapp, 2001) and their health‐related quality of life (e.g., EQ‐5D‐3L; Brooks, 1996).
Several guidelines have been published in recent years on the issue of missing data in clinical trials (National
Research Council, 2010; Committee for Medicinal Products for Human Use (CHMP), 2011; Burzykowski et al., 2010;
Carpenter & Kenward, 2007) and for CEA in particular (Briggs, Clark, Wolstenholme, & Clarke, 2003; Burton,
Billingham, & Bryan, 2007; Faria, Gomes, Epstein, & White, 2014; Manca & Palmer, 2005; Marshall, Billingham, &
Bryan, 2009). Key recommendations include:
• taking practical steps to limit the number of missing observations;
• avoiding methods whose validity rests on contextually implausible assumptions, and using methods that incorporate
all available information under reasonable assumptions; and
• assessing the sensitivity of the results to departures from these assumptions.
In particular, following Rubin's taxonomy of missing data mechanisms (Little & Rubin, 2002), methods valid under a
missing‐at‐random (MAR) assumption (i.e., when, given the observed data, missingness does not depend on the unseen
values) appear more plausible than the more restrictive assumption of missing completely at random, where missingness
is assumed to be entirely independent of the variables of interest. Because we cannot exclude the possibility that the
missingness may depend on unobserved values (missing not at random [MNAR]), an assessment of the robustness of
the conclusions to alternative missing data assumptions should also be undertaken.
Noble and colleagues (Noble, Hollingworth, & Tilling, 2012) have previously reviewed how missing resource use data
were addressed in trial‐based CEA. They found that practice fell markedly short of recommendations in several aspects.
In particular, that reporting was usually poor and that complete‐case analysis was the most common approach. How-
ever, missing data research is a rapidly evolving area, and several of the key guidelines were published after that review.
We therefore aimed to review how missing cost‐effectiveness data were addressed in recent trial‐based CEA.
We reviewed studies published in the National Institute for Health Research Health Technology Assessment (HTA)
journal, as it provides an ideal source for assessing whether recommendations have permeated CEA practice. These
reports give substantially more information than a typical medical journal article, allowing authors the space to clearly
describe the issues raised by missing data in their study and the methods they used to address these. Our primary objec-
tives were to determine the extent of missing data, how these were addressed in the analysis, and whether sensitivity
analyses to different missing data assumptions were performed. We also provide a critical review of our findings and rec-
ommendations to improve practice.
2 | METHODS
The PubMed database was used to identify all trial‐based CEA published in HTA between the January 1, 2013, and
December 31, 2015. We combined search terms such as “randomised,” “trial,” “cost,” or “economic” to capture rel-
evant articles (see Appendix A.1 for details of the search strategy). The full reports of these articles were downloaded
then screened for eligibility by excluding all studies that were pilot or feasibility studies; reported costs and effects
separately (e.g., cost‐consequence analysis); or did not report a within‐trial CEA.
For each included study, we extracted key information about the study and the analysis to answer our primary
research questions. A detailed definition of each indicator extracted is provided in Appendix B. In a second stage, we drew
on published guidelines and our experience to derive a list of recommendations to address missing data, and then re‐
reviewed the studies to assess to which extent they followed these recommendations (see Appendix B for further details).
Data analysis was conducted with Stata version 15 (StataCorp, 2017). The data from this review are available on
request (Leurent, Gomes, & Carpenter, 2017).
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3 | RESULTS
3.1 | Included studies
Sixty‐five articles were identified in our search (Figure 1), and 52 eligible studies were included in the review (listed in
Appendix A.2). The median time frame for the CEA was over 12 months, and the majority of trials (71%, n = 37) con-
ducted a follow‐up with repeated assessments over time (median of 2; Table 1). The most common effectiveness measure
was the quality‐adjusted life year (81%, n = 42). Other outcomes included score on clinical measures, or dichotomous
outcomes such as “smoking status”.
3.2 | Extent of missing data
Missing data was an issue in almost all studies, with only five studies (10%) having less than 5% of participants
with missing data. The median proportion of complete cases was 63% (interquartile range, 47–81%; Figure 2). Miss-
ing data arose mostly from patient‐reported (e.g., resource use and quality of life) questionnaires. The extent of
missing data was generally similar for cost and effectiveness data, but 10 (19%) studies had more missing data in
the latter (Table 1). The proportion of complete cases reduced, as the number of follow‐up assessments increased
(Spearman's rank correlation coefficient ρ = −0.59, p value < .001) and as the study duration increased
(ρ = −0.29, p = .04).
3.3 | Approach to missing data
In the remaining assessments, we excluded the five studies with over 95% of complete cases. Three main approaches to
missing data were used: complete‐case analysis (CCA; Faria et al., 2014), reported in 66% of studies (n = 31), multiple
imputation (MI; Rubin, 1987; 49%, n = 23), and ad hoc hybrid methods (17%, n = 8). For the primary analysis, CCA
FIGURE 1 Studies selection flow diagram. CEA = cost‐effectiveness analyses; HTA = health technology assessment; RCT = randomised
controlled trial
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was the most commonly used method (43%, n = 20), followed by MI (30%, n = 14; Table 2). MI was more common when
the proportion of missing data was high and when there were multiple follow‐up assessments (see Table 3).
3.4 | Sensitivity analyses
Over half of the studies (53%, n = 25) did not conduct any sensitivity analysis around missing data, with 21% (n = 10)
reporting CCA results alone and 11% (n = 5) MI results under MAR alone (Table 4). The remaining studies (n = 22,
47%) assessed the sensitivity of their primary analysis results to other approaches for the missing data. This was usually
performing either MI under MAR, or CCA, when the other approach was used in the primary analysis. Other sensitivity
analyses included using last observation carried forward or regression imputation.
Only two studies (4%) conducted sensitivity analyses, assuming data could be MNAR. In both studies, values
imputed under a standard MI were modified to incorporate possible departures from the MAR assumption for both
TABLE 1 Characteristics of included studies (n = 52)
n %
Median (IQR)
General characteristics
Publication year
2013 14 27
2014 15 29
2015 23 44
CEA time frame
0–11 months 22 42
12 months 19 37
≥24 months 11 21
Follow‐up design
Continuous (time to event) 4 8
One follow‐up assessment 11 21
Repeated assessments 37 71
Effectiveness measure
QALY 42 81
Binary 6 12
Clinical scale score 3 6
Time to recovery 1 2
Missing data
Report exact number of complete cases 20 38
Proportion of complete casesa 0.63 (0.47–0.81)
Proportion complete effectiveness data (n = 47) 0.73 (0.55–0.86)
Proportion complete cost data (n = 40) 0.79 (0.67–0.92)
Differs between costs and effectivenessb
Yes, more cost data missing 3 6
Yes, more effect data missing 10 19
No 22 42
No missing (<5%) 5 10
Unclear 12 23
Differs between armsc
Yes 10 19
No 32 62
No missing (<5%) 5 10
Unclear 5 10
Note. IQR = interquartile range; QALY = quality‐adjusted life year.
aProportion of trial participants with complete cost‐effectiveness data. An upper bound was used if exact number not reported.
bMore than 5% difference in the proportion of participants with complete cost or effectiveness data.
cMore than 5% difference in the proportion of complete cases between arms.
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FIGURE 2 Proportion of trial participants with complete data for the primary cost‐effectiveness analysis. Shown for cost‐effectiveness
(n = 52), effectiveness (n = 47, unclear in 5 studies), and cost data (n = 40, unclear in 12 studies)
TABLE 2 Methods for handling missing data in primary analysis (n = 47)
Primary analysis method n %
Complete‐case analysis 20 43
Multiple imputation 14 30
Other—single methods
Inverse probability weighting 1 2
Bayesian model, missing data as unknown parameter 1 2
Other—ad hoc hybrid methodsa 8 17
Using a combination of
Mean imputationb 6
Regression imputationc 3
Inverse probability weightingd 2
Assuming failure when outcome missing 2
Multiple imputation 1
Last observation carried forward 1
Unclear 3 6
aAd hoc hybrid method = several approaches to missing data combined, for example, using mean imputation for missing individual resource use
items and multiple imputation for fully incomplete observations.
bMean imputation = replacing missing values by the average across other participants.
cRegression imputation = replace missing values by predicted value based on observed variables.
dInverse probability weighting = analysing complete data, weighted according to their modelled probability of being observed. These methods are
presented in more details in other references (Baio & Leurent, 2016; Faria et al., 2014).
LEURENT ET AL. 5
the cost and effectiveness data using a simplified pattern‐mixture model approach (Faria et al., 2014; Leurent et al.,
2018). The studies then discussed the plausibility of these departures from MAR and their implications for the cost‐
effectiveness inferences.
3.5 | Recommendations criteria
Table 5 reports the number of studies that reported evidence of following the recommendations from Figure 3 (see
Section 4). Most studies reported being aware of the risk of missing data, for example, by taking active steps to reduce
them (n = 35, 74%). In addition, almost two‐thirds of the studies (n = 29, 62%) reported the breakdown of missing data
by arm, time point, and endpoint. Only about one‐third of the studies have clearly reported the reasons for the missing
TABLE 3 Approaches to missing data, by year, number of follow‐ups, and extent of missing data (n = 47)
Primary analysis method Reported a sensitivity analysis
CCA MI Other Yes No
n % n % n % n % n %
Publication year
2013 (n = 13) 6 46 3 23 4 31 5 38 8 62
2014 (n = 15) 9 60 1 7 5 33 6 40 9 60
2015 (n = 19) 5 26 10 53 4 21 11 58 8 42
Number of follow‐up assessmentsa
1 (n = 10) 7 70 1 10 2 20 3 30 7 70
≥2 (n = 36) 13 36 13 36 10 28 18 50 18 50
Proportion of complete casesb
<50% (n = 15) 4 27 6 40 5 33 8 53 7 47
50–75% (n = 18) 10 56 4 22 4 22 9 50 9 50
75%–95% (n = 14) 6 43 4 29 4 29 5 36 9 64
Information missingc
Similar (n = 22) 13 59 6 27 3 14 10 45 12 55
More cost missing (n = 3) 1 33 2 67 0 0 2 67 1 33
More effect missing (n = 10) 4 40 2 20 4 40 6 60 4 40
Note. % = row percentages. CCA = complete‐case analysis; MI = multiple imputation.
aExcluding one study with continuous follow‐up (n = 46).
bFor the five studies with less than 5% of incomplete cases, four used CCA and one an ad hoc hybrid method for their primary analysis. One of the
five studies conducted a sensitivity analysis to missing data.
cExcluding 12 studies where this was unclear (n = 35).
TABLE 4 Sensitivity analysis, overall, and by primary analysis method (n = 47)
None
Sensitivity analysis method
CCA MI (MAR) MNAR Othera
n % n % n % n % n %
Overall
Total (n = 47) 25 53 11 23 9 19 2 4 5 11
By primary analysis
CCA (n = 20) 10 50 0 0 8 40 0 0 2 10
MI (n = 14) 5 36 9 64 0 0 2 14 2 14
Other (n = 13) 10 77 2 15 1 8 0 0 1 8
Note. % = row percentages; CCA = complete‐case analysis; MAR = assuming data missing at random; MI = multiple imputation; MNAR = assuming
data missing not at random. Total may be more than 100% as some studies conducted more than one sensitivity analysis.
aOther methods used for sensitivity analysis include last observation carried forward (n = 1), regression imputation (n = 1), adjusting for baseline pre-
dictors of missingness (n = 1), imputing by average of observed values for that patient (n = 1), and an ad hoc hybrid method using multiple and mean
imputation (n = 1).
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data (n = 16, 34%) and the approach used for handling the missing data and its underlying assumptions (n = 17, 36%).
Only one study (2%) appropriately discussed the implications of missing data in their cost‐effectiveness conclusions.
4 | DISCUSSION
4.1 | Summary of findings
Missing data remain ubiquitous in trial‐based CEA. The median proportion of participants with complete cost‐effective-
ness data was only 63%. This reflects the typical challenges faced by CEA of randomised controlled trials, which often
rely on patient questionnaires to collect key resource use and health outcome data. Despite best efforts to ensure
TABLE 5 Review of indicators based on recommendations criteria (n = 47)
Criteriona
Metb Not met Unclear
n % n % n %
Prevent
A1. Maximise response rate 35 74 12 26 0 0
A2. Alternative data sources 10 21 37 79 0 0
A3. Monitor completeness 17 36 30 64 0 0
Primary
B1. Assumption for primary analysis 17 36 27 57 3 6
B2. Appropriate primary method 17 36 27 57 3 6
Sensitivity
C1. Discuss departures from the primary assumption 0 0 47 100 0 0
C2. Consider broad range of assumptions 2 4 45 96 0 0
C3. Method valid under these assumptions 2 4 45 96 0 0
Report
D1. Missing data by endpoint, arm, and time point 29 62 18 38 0 0
D2. Discuss reasons for missing data 16 34 31 66 0 0
D3. Describe methods used and assumptions 17 36 30 64 0 0
D4. Conclusions in light of missing data 1 2 46 98 0 0
aSee Figure 3 and Appendix B for definition of each criterion.
bReport demonstrates evidence of having followed this recommendation. Not met if the recommendation was not followed or not mentioned. Unclear if
some suggestions the criteria may have been met but information not clear enough. See Appendix B for detailed definitions and methodology used.
FIGURE 3 Recommendations for
improving handling of missing data in
trial‐based cost‐effectiveness analysis.
References: 1, Little et al., 2012; 2, Noble
et al., 2012; 3, Faria et al., 2014; and 4,
Carpenter and Kenward 2007
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completeness, a significant proportion of nonresponse is likely. This is consistent with other reviews, which also found
no reduction of the extent of missing data in trials over time (Bell et al., 2014).
CCA remains the most commonly used approach for handling missing data in trial‐based CEA, in contrast to rec-
ommendations. This approach makes the restrictive assumption that, given the variables in the analysis model, the
distributions of the outcome data are the same, whether or not those outcome data are observed. This approach is
also problematic because it can result in a loss in precision, as it discards participants who have partially complete
data postrandomisation and who can provide important information to the analysis. Other unsatisfactory approaches
based on unrealistic assumptions, such as last observation carried forward and single imputation, are also occasion-
ally used.
MI (Rubin, 1987) assuming MAR has been widely recommended for CEA (Briggs et al., 2003; Burton et al., 2007;
Faria et al., 2014; Marshall et al., 2009), allowing for baseline variables and postrandomisation data not in the primary
analysis to be used for the imputation. It seems to be now more commonly used, with around half of the studies using
MI for at least one of their analyses (up to 74% in 2015). Around one‐third of the studies used MI for their primary CEA,
which is higher than seen in primary clinical outcome analyses (8%; Bell et al., 2014).
On the other hand, sensitivity analyses to missing data remain clearly insufficient. Only two studies (4%) conducted
comprehensive sensitivity analyses and assessed whether the study's conclusions were sensitive to departures from the
MAR assumption (i.e., possible MNAR mechanisms). Half of the studies did not conduct any sensitivity analysis regard-
ing the missing data. The remaining studies performed some sort of sensitivity analyses, but usually consisting of simple
variations from the primary analysis, such as reporting CCA results in addition to MI. This may be more for complete-
ness than proper missing data sensitivity analyses. For example, if MI is used for the primary analysis (having assumed
that MAR is the realistic primary missing data assumption), a sensitivity analysis that involves CCA will make stronger
missing data assumptions.
4.2 | Strengths and limitations
Our review follows naturally from the review of Noble et al. (2012) and gives an update of the state of play after the
publication of several key guidelines. Our review, however, differs in scope and methods and cannot be directly com-
pared with the results of Noble et al. One of the key strengths of this review is that HTA comprehensive reports
allowed us to obtain a more complete picture of the missing data and the methods used to tackle it. HTA mono-
graphs are published alongside more succinct peer‐reviewed papers in specialist medical journals, and they are often
seen as the “gold‐standard” for trial‐based CEA in the UK. It seems therefore reasonable to assume that these are
representative of typical practice in CEA. This review is, to our knowledge, the first to look at completeness of both
cost and effectiveness data. A limitation is the use of a single‐indicator “proportion of complete cases” to capture the
extent of the missing data issue. This is however a clearly defined indicator and allows comparison with other
reviews. The “recommendations indicators” also focused on the information reported in the study, not necessarily
what might have been done in practice.
4.3 | Recommendations
A list of recommendations to address missing data in trial‐based CEA is presented in Figure 3. Trial‐based CEA are prone
to missing data, and it is important that analysts take active steps at the design and data‐collection stages to limit their
extent (Bernhard et al., 2006; Brueton et al., 2013; National Research Council, 2010). Resource use questionnaires should
be designed in a user‐friendly way, and their completion encouraged during follow‐up visits, possibly supported by a
researcher (Mercieca‐Bebber et al., 2016; National Research Council, 2010). Alternative sources should also be consid-
ered to minimise missing information, for example, administrative data or electronic health records (Franklin & Thorn,
2018; Noble et al., 2012).
For any study with missing data, clear reporting of the issue is required. Ideally, the study should report details of the
pattern of missing data (Faria et al., 2014), possibly as an appendix. At a minimum, CEA studies should report for each
analysis the number of participants included by trial arm, as recommended in the Consolidated Standards of Reporting
Trials guidelines (Noble et al., 2012; Schulz et al., 2010).
Although CCA may be justifiable in some circumstances, the choice of CCA for the primary analysis approach
appears difficult to justify in the presence of repeated measurements, because the loss of power (by discarding all patients
with any missing values) across the different time points tends to be large. Other approaches valid under more plausible
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MAR assumptions and making use of all the observed data, such as MI (Rubin, 1987); likelihood‐based repeated mea-
sures models (Faria et al., 2014; Verbeke, Fieuws, Molenberghs, & Davidian, 2014); or Bayesian models (Ades et al.,
2006), should be considered. In particular, MI has been increasingly used in CEA, and further guidance to support an
appropriate use in this context is warranted.
An area with clear room for improvement is the conduct of sensitivity analyses. This review found that many studies
used CCA for the primary analysis and MI as a sensitivity analysis, or vice‐versa, and concluded that the results were
robust to missing data. This is misleading because both of these methods rely on the assumption that the missingness
is independent of the unobserved data. Although the MAR assumption provides a sensible starting point, it is not pos-
sible to determine the true missing‐data mechanism from the observed data. Studies should therefore assess whether
their conclusions are sensitive to possible departures from that assumption (National Research Council, 2010; Commit-
tee for Medicinal Products for Human Use (CHMP), 2011; Faria et al., 2014). Several approaches have been suggested to
conduct analyses under MNAR assumptions. Selection models express how the probability of being missing is related to
the value itself. Pattern‐mixture models, on the other hand, capture how missing data could differ from the observed
(Molenberghs et al., 2014; Ratitch, O'Kelly, & Tosiello, 2013). Pattern‐mixture models appear attractive because they
frame the departure from MAR in a way that can be more readily understood by clinical experts and decision makers
and can be used with standard analysis methods such as MI (Carpenter & Kenward, 2012; Ratitch et al., 2013). MNAR
modelling can be challenging, but accessible approaches have also been proposed (Faria et al., 2014; Leurent et al., 2018).
Further developments are still needed to use these methods in the CEA context and to provide the analytical tools and
practical guidance to implement them in practice.
5 | CONCLUSION
Missing data can be an important source of bias and uncertainty, and it is imperative that this issue is appropriately
recognised and addressed to help ensure that CEA studies provide sound evidence for healthcare decision making. Over
the last decade, there have been some welcome improvements in handling missing data in trial‐based CEA. In particular,
more attention has been devoted to assessing the reasons for the missing data and adopting methods (e.g., MI) that can
incorporate those in the analysis. However, there is substantial room for improvement. Firstly, more efforts are needed to
reduce missing data. Secondly, the extent and patterns of missing data should be more clearly reported. Thirdly, the pri-
mary analysis should consider methods that make contextually plausible assumptions rather than resort automatically to
CCA. Lastly, sensitivity analyses to assess the robustness of the study's results to potential MNAR mechanisms should be
conducted.
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APPENDIX B
INDICATORS DEFINITION
B.1 | Primary indicators
Indicator Definition Notes
Proportion of complete cases Proportion of randomised participants for
whom all data were available for the
primary cost‐effectiveness analysis
If the number of complete‐cases was not
clearly reported, we estimated an
“upper bound,” from information, such
as the proportion of participants with
complete cost, or effect, data. See
definition of primary analysis below.
Proportion complete effectiveness data Proportion of randomised participants for
whom all effectiveness data were
Available for the primary cost‐
effectiveness analysis
Same as above
Proportion complete cost data Proportion of randomised participants for
whom all cost data were available for
the primary cost‐effectiveness analysis
Same as above
Report exact number of complete cases Whether the number of participants with
complete cost and effectiveness data
was clearly reported.
More missing costs or effectiveness Whether the proportion of complete cases
differ between cost and effectiveness
variable.
Considered “similar” when the
proportion of complete cases was
within 5% of each other.
Primary analysis method Methods used to address missing data in
the primary (base case) cost‐
effectiveness analysis
When multiple effectiveness measures,
time‐frames, or cost perspectives were
reported, without a base‐case clearly
defined, we considered the analysis
based on quality‐adjusted life years
(QALYs) over the longest within‐trial
follow‐up period, from the NHS and
social services cost perceptive.
Conducted a sensitivity analysis to
missing data
Report results under more than one
approach for addressing missing data
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B.2 | Secondary indicators: Derived from the recommendations list
B.2.1 | Methods
Because these aspects could have been mentioned in multiple parts in the monograph, we used a systematic approach,
looking for keywords and checking the most relevant paragraphs in the full report.
i. Search in PDF: “Missing”; “Participation”; “Completion”; “Incomplete”; “Response”; “Non‐response”; “Monitor”;
“MCAR”; “MAR”; “MNAR.”
ii. If did not find “steps to reduce missing data,” also check “reminder,” “incentive,” “telephone,” and “contact.”
iii. Then, check relevant paragraphs manually: data source for cost‐effectiveness data; beginning of CEA results; and
CEA conclusions.
B.2.2 | Answers
“Yes”: The recommendation was clearly mentioned, and the criteria therefore met.
“No”: The recommendation was not clearly mentioned or found. The recommendation may still have been followed
but not reported (or at least not found with the above strategy).
“Unclear”: There was some suggestions the criteria may have been met but not enough information to be sure.
Recommendation Indicator definition Examples “yes” Examples “no” Notes
A1. Maximise response
rate (consider
questionnaire design,
mode of administration,
reminders, incentives,
participants'
engagement, etc.)
Mention taking steps to
maximise response rate
Reminder, incentives,
home/hospital visit,
multiple attempts,
Mention response was
maximised for clinical
outcome but not reported
for cost‐effectiveness
endpoints
Can be for overall trial data if implicit
includes cost or effect data. Except
if steps are clearly for non‐CE
variables only (e.g., primary
outcome only).
A2. Consider alternative
data sources (e.g.,
routinely collected data)
Mention that considered
missing data issues when
choosing appropriate
source, OR mention more
than one source used for a
CE data.
Use of electronic health
records or administrative
data, e.g., hospital episode
statistics were used to
supplement trial's data,
for example, about
hospital admissions post‐
randomisation (which
might be otherwise
missing).
Using routine data as a
primary source: e.g.,
resource use taken
primarily from
administrative/hospital
records.
A3. Monitor cost‐
effectiveness data
completeness while trial
ongoing
Mentioned monitoring data
completeness while trial
ongoing.
Data managers checked
inconsistent and missing
data (if not clear “while
trial ongoing” but
mention monitoring
probably fine). Mention
taking new steps to
reduce MD (e.g.,
incentive) as realised lots
of MD after trial started.
Mention data checks for
inconsistencies, but no
mention of checking
missing data.
Can be for overall trial data. Except if
monitoring clearly for non‐CE
variables only (e.g., primary
outcome only).
B1. Formulate realistic and
accessible missing data
assumption for the
primary analysis
(typically, but not
necessarily, a form of the
missing at random
assumption)
Primary (base‐case) CEA
based on reasonable
missing data
assumptions. (likely
MAR, or alternative if
well justified).
– Used MI for primary
analysis ‐ well justified
and clear alternative
– Hybrid method, except if
clearly explain and justify
underlying assumptions
(Continues)
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(Continued)
Recommendation Indicator definition Examples “yes” Examples “no” Notes
B2. Use appropriate
method valid under that
assumption (typically,
but not necessarily,
multiple imputation or
maximum likelihood)
Use appropriate analysis
method.
– MI for primary analysis ‐
Bayesian under MAR ‐
well justified and clear
alternative
– Use unadjusted CCA
when reporting data are
MAR.
C1. Discuss with clinicians
and investigators to
formulate plausible
departures from the
primary missing data
assumption
Conducted MNAR
SA + mention elicitation.
Did not conduct MNAR SA
C2. Consider a broad range
of assumptions,
including missing not at
random mechanisms
Conducted MNAR SA Did not conduct MNAR SA
C3. Use appropriate
method valid under
these assumptions
(typically, but not
necessarily, pattern‐
mixture models or
reference‐based
approach)
Conducted MNAR SA, and
used an appropriate
method (PMM, etc.).
Did not conduct MNAR SA
D1. Report number of
participants with cost
and outcome data, by
arm and time‐point
Report number (or %) of
complete or missing data.
Split at least by
effectiveness vs. cost, time
point (when applicable),
and arm
Reported missing data by
endpoint and arm, but
not by time point.
Do not have to be all at the same time
(split by endpoint + time + arm),
can be three separate table/texts.
D2. Report possible
reasons for non‐
response, and baseline
predictors of missing
values
Mention something about
main reason for the
missing data, OR Explore
factors associated with it.
Comment on why missing
data (e.g., “because
patients were too ill”). Or
explore baseline factors
associated with
missingness
No mention of reasons for
MD in the CE section.
Have to be specific to the CE missing
data, or clearly mentioning
something like “reasons for MD are
discussed in clinical analysis
section …”
D3. Describe methods
used, and underlying
missing data
assumptions
Clearly state the method
used to address missing
data, AND the underlying
assumption.
No report of missing data
assumption or method
used
Draw overall conclusion in
light of the different
results and the
plausibility of the
respective assumptions
Conduct sensitivity
analyses, and interpret
results appropriately.
Did MNAR SA and
appropriate conclusion.
– Did not conduct sensitivity
analyses
– Conducted sensitivity
analyses, but no
comment/conclusion
– Did MI and CC and only
say “results did not
change/robust to missing
data”
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